Indium-111 diethylenetriaminepentaacetate adenosylcobalamin - Mayo Clinic/Naviscan PET Systems
Alternative Names: DTPA-adenosylcobalamin; In 111 DACLatest Information Update: 04 Nov 2017
At a glance
- Originator Mayo Clinic
- Developer Mayo Clinic; Naviscan PET Systems
- Class Heavy metals; Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer(Diagnosis) in USA (Parenteral, Injection)
- 10 Dec 2007 In 111 DAC is still in phase I trials for Diagnostic Imaging in USA
- 01 Dec 2005 Mayo Clinic and Naviscan PET Systems have entered into licensing agreement for use of In 111 DAC as molecular imaging agent in cancer patients